These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110 [TBL] [Abstract][Full Text] [Related]
16. Safety of 5914 intravitreal ziv-aflibercept injections. Singh SR; Stewart MW; Chattannavar G; Ashraf M; Souka A; ElDardeery M; Wadhwa N; Sarvaiya C; Mansour AM; Marashi A; Ramchandani S; Braimah IZ; Jabbarpoor Bonyadi MH; Ramezani A; Soheilian M; de Oliveira Dias JR; de Andrade GC; Maia A; Rodrigues EB; Farah ME; Banker A; Chhablani J; Br J Ophthalmol; 2019 Jun; 103(6):805-810. PubMed ID: 30099379 [TBL] [Abstract][Full Text] [Related]
17. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies. Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825 [TBL] [Abstract][Full Text] [Related]
18. FLATTENING OF A TREATMENT-RESISTANT RETINAL PIGMENT EPITHELIAL DETACHMENT AFTER A SINGLE INTRAVITREAL INJECTION OF ZIV-AFLIBERCEPT. Yogi R; Stewart M; Chhablani J Retin Cases Brief Rep; 2017 Spring; 11(2):111-113. PubMed ID: 27078613 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192 [TBL] [Abstract][Full Text] [Related]
20. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden. Bro T; Hägg S Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]